|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTSO |
Gene summary for CTSO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTSO | Gene ID | 1519 |
| Gene name | cathepsin O | |
| Gene Alias | CTSO1 | |
| Cytomap | 4q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P43234 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1519 | CTSO | S43 | Human | Liver | Cirrhotic | 1.08e-02 | -7.41e-02 | -0.0187 |
| 1519 | CTSO | HCC1_Meng | Human | Liver | HCC | 2.39e-21 | -6.49e-02 | 0.0246 |
| 1519 | CTSO | HCC2_Meng | Human | Liver | HCC | 7.41e-09 | -6.03e-02 | 0.0107 |
| 1519 | CTSO | cirrhotic2 | Human | Liver | Cirrhotic | 1.15e-03 | 1.31e-01 | 0.0201 |
| 1519 | CTSO | Pt13.b | Human | Liver | HCC | 3.90e-02 | 2.51e-02 | 0.0251 |
| 1519 | CTSO | S027 | Human | Liver | HCC | 9.84e-06 | 6.92e-01 | 0.2446 |
| 1519 | CTSO | S028 | Human | Liver | HCC | 3.29e-11 | 7.37e-01 | 0.2503 |
| 1519 | CTSO | S029 | Human | Liver | HCC | 1.62e-07 | 7.96e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041424 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
| hsa042106 | Liver | Cirrhotic | Apoptosis | 58/2530 | 136/8465 | 9.84e-04 | 5.55e-03 | 3.42e-03 | 58 |
| hsa0414211 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
| hsa0421011 | Liver | Cirrhotic | Apoptosis | 58/2530 | 136/8465 | 9.84e-04 | 5.55e-03 | 3.42e-03 | 58 |
| hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| hsa042102 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
| hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| hsa042103 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTSO | SNV | Missense_Mutation | c.281N>T | p.Arg94Ile | p.R94I | P43234 | protein_coding | deleterious(0.01) | benign(0.013) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| CTSO | SNV | Missense_Mutation | c.310N>T | p.Pro104Ser | p.P104S | P43234 | protein_coding | tolerated(0.62) | benign(0) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| CTSO | SNV | Missense_Mutation | c.892N>A | p.Asp298Asn | p.D298N | P43234 | protein_coding | tolerated(0.08) | benign(0.02) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| CTSO | SNV | Missense_Mutation | rs376990374 | c.155G>A | p.Arg52Gln | p.R52Q | P43234 | protein_coding | tolerated(0.15) | benign(0.036) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CTSO | SNV | Missense_Mutation | c.737A>T | p.Asp246Val | p.D246V | P43234 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| CTSO | SNV | Missense_Mutation | c.877N>C | p.Ser293Arg | p.S293R | P43234 | protein_coding | tolerated(0.49) | benign(0.076) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CTSO | SNV | Missense_Mutation | c.796G>A | p.Glu266Lys | p.E266K | P43234 | protein_coding | tolerated(0.22) | benign(0.021) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CTSO | SNV | Missense_Mutation | novel | c.181N>A | p.Glu61Lys | p.E61K | P43234 | protein_coding | tolerated(0.14) | benign(0.05) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| CTSO | SNV | Missense_Mutation | c.586N>A | p.Pro196Thr | p.P196T | P43234 | protein_coding | tolerated(0.15) | possibly_damaging(0.841) | TCGA-NH-A8F7-06 | Colorectum | NA | NA | NA | NA | NA | NA | NA | |
| CTSO | SNV | Missense_Mutation | c.838N>A | p.Gly280Arg | p.G280R | P43234 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1519 | CTSO | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL481611 | ODANACATIB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |